Antithrombotic stewardship (ATS) is a practical, evidence-based care model slowly gaining traction across the globe [1,2]. The impetus for this trend is the persistent evidence for low-quality thrombosis-related care and the high incidence of anticoagulation-related adverse events, many of which are avoidable with proper management [2]. The opportunities for improved care delivery and patient outcomes are significant. Historically, about 2 % of populations of developed countries were prescribed anticoagulants, predominantly for stroke prevention in atrial fibrillation (AF), the prevention and treatment of venous thromboembolism (VTE), and stroke prevention in patients with prosthetic heart valves.
